Case Report: Long-term disease-free survival in an advanced hepatocellular carcinoma patient: an exceptional response to PD-1 inhibitor therapy
This case highlights the potential for long-term survival with reduced-dose PD-1 inhibitor therapy in advanced HCC. The patient's exceptional response provides important insights into the role of personalized dosing, immune checkpoint inhibitors, and the management of immune-related adverse events.
Authors
- Qinliang Fang
- Yu Xiong
- Jianyin Zhou (ORCID: https://orcid.org/0000-0002-4396-4518)
- Shuqi Yu
- Yibin Zhang (ORCID: https://orcid.org/0000-0003-0894-9256)
- Xiaomin Wang (ORCID: https://orcid.org/0000-0001-6235-3061)
- Fuqiang Wang (ORCID: https://orcid.org/0000-0002-7777-3541)
- Zhenyu Yin (ORCID: https://orcid.org/0000-0002-1763-8460)
Institutions
- Xiamen University (CN)
- Zhongshan Hospital of Xiamen University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.3389/fimmu.2025.1677724
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province